Concordantly, combined inhibition of JAK and MEK effectively controls juvenile myelomonocytic leukemia and a myeloproliferative variant of chronic myelomonocytic leukemia NRASG12D/G12D mice (64). The gene discussed is MAP2K7; the disease is chronic myelomonocytic leukemia.